Immunoglobulin-G level on aggressive periodontitis patients treated with clindamycin

• Egile nagusia: Agung Krismariono (Egilea)
• Formatua: Liburua
• Argitaratua: Universitas Airlangga, 2009-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Gaia

<span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Background: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Aggressive periodontitis might occur as a result of complex interplay between bacteria and host defence, therefore, </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>the host susceptibility plays important role. Antimicrobial agents that could enhance host defence are required. Clindamycin might </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>influence host defence. </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Purpose: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>The purpose of this study was to determine the influence of clindamycin on level of Immunoglobulin-G </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>(IgG) patients with aggressive periodontitis, and its mechanism. </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Methods: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>This study used the pre-test post-test control group design. </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Eighteen aggressive periodontitis patients were divided into 2 groups at random. Group 1 (treatment): 9 aggressive periodontitis </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>patients were given with clindamycin of 150mg orally, 4 times a day, for 7 days. Group 2 (control): 9 aggressive periodontitis patients </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>were given with tetracycline of 250mg orally, 4 times a day for 12 days, and then metronidazole of 200mg orally, 3 times a day for </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>10 days. Blood sample was collected from vena cubiti mediana. Level of IgG was measured at base line and day 28. Data were analyzed </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>statistically by using t-test (</em><span style="font-family: SymbolProportionalBT-Regular; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;">a <span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>= 0.05). </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Result: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>Examination for IgG level showed there was significant difference between pre-test and </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>post-test (p < 0.05). Level of IgG was significantly increased after therapy, both in treatment and control group. The increase of IgG </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>level in treatment group was not different significantly from control group (p>0.05). </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Conclusions: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>This study shows that clindamycin </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>can be used as drug of choice for the treatment of aggressive periodontitis since clindamycin can improve the immunity status of </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>aggressive periodontitis patients.</em></span></span></span></span></span></span></span></span></span></span></span></span><br style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;" /></span></span></span></span></span></span></span></span></span></span></span></span>

Alearen deskribapena

1978-3728
2442-9740
10.20473/j.djmkg.v42.i3.p118-122